Literature DB >> 24327422

Effect of a randomized controlled trial on the surgical treatment of spinal metastasis, 2000 through 2010: a population-based cohort study.

Michael L Kelly1, Varun R Kshettry, Benjamin P Rosenbaum, Andreea Seicean, Robert J Weil.   

Abstract

BACKGROUND: The effect of randomized controlled trials (RCT) on clinical practice patterns and patient outcomes is understudied. A 2005 RCT by Patchell et al demonstrated benefit for surgical decompression in patients with spinal metastasis (SpM). We examined trends in spinal surgery for patients with SpM before and after publication of the Patchell RCT.
METHODS: The Nationwide Inpatient Sample (NIS) was used to identify a 20% stratified sample of surgical SpM admissions to nonfederal United States hospitals from 2000 to 2004 and 2006 to 2010, excluding 2005 when the RCT was published. Propensity scores were generated and logistic regression analysis was performed to compare outcomes in pre- and post-RCT time periods.
RESULTS: A total of 7404 surgical admissions were identified. The rate of spine surgery increased post-RCT from an average of 3.8% to 4.9% surgeries per metastatic admission per year (P = .03). Admissions in the post-RCT group were more likely to be non-Caucasian, lower income, Medicaid recipients, and have more medical comorbidities and a greater metastatic burden (P < .001). Logistic regression of the propensity-matched sample showed increased odds post-RCT for expensive hospital stay (2.9; 95% confidence interval [CI] = 2.6-3.4) and some complications, including neurologic (1.7; 95% CI = 1.1-2.8), venous thromboembolism (2.8; 95% CI = 1.9-4.2), and decubitis ulcers (15.4; 95% CI = 6.7-34.5). However, odds for in-hospital mortality decreased (0.6; 95% CI = 0.5-0.8).
CONCLUSIONS: Surgery for SpM increased after publication of a positive RCT. A significantly greater proportion of patients with lower socioeconomic status, more comorbidities, and greater metastatic burden underwent surgery post-RCT. These patients experienced more postoperative complications and higher in-hospital charges but less in-hospital mortality.
© 2013 American Cancer Society.

Entities:  

Keywords:  Nationwide Inpatient Sample; outcomes assessment; randomized controlled trial; spinal metastasis; validity of results

Mesh:

Year:  2013        PMID: 24327422     DOI: 10.1002/cncr.28497

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Factors influencing early postoperative complications following surgery for symptomatic spinal metastasis: a single-center series and multivariate analysis.

Authors:  Patrick Schuss; Ági Güresir; Matthias Schneider; Markus Velten; Hartmut Vatter; Erdem Güresir
Journal:  Neurosurg Rev       Date:  2018-09-15       Impact factor: 3.042

2.  SPINE METASTASIS OF INTRACRANIAL HEMANGIOPERICYTOMA: CASE REPORT OF TWO TREATMENTS.

Authors:  Fernando Flores de Araujo; Douglas Kenji Narazaki; William Gemio Jacobsen Teixeira; Raphael Martus Marcon; Alexandre Fogaça Cristante; Tarcísio Eloy Pessoa Barros
Journal:  Acta Ortop Bras       Date:  2019 Mar-Apr       Impact factor: 0.513

3.  Impact of surgical intervention trials on healthcare: A systematic review of assessment methods, healthcare outcomes, and determinants.

Authors:  Juliëtte J C M van Munster; Amir H Zamanipoor Najafabadi; Nick P de Boer; Wilco C Peul; Wilbert B van den Hout; Peter Paul G van Benthem
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

4.  Trends in Utilization of Preoperative Embolization for Spinal Metastases: A Study of the National Inpatient Sample 2005-2017.

Authors:  Waseem Wahood; Alex Yohan Alexander; Yagiz Ugur Yolcu; Waleed Brinjikji; David F Kallmes; Giuseppe Lanzino; Mohamad Bydon
Journal:  Neurointervention       Date:  2021-02-04

5.  Survival and clinical outcomes in patients with metastatic epidural spinal cord compression after spinal surgery: a prospective, multicenter, observational cohort study.

Authors:  Anick Nater; Michael G Fehlings
Journal:  Chin J Cancer       Date:  2016-03-16

6.  Outcomes and prognostic factors for surgically treated patients with breast cancer spine metastases.

Authors:  Chenglong Zhao; Zhichao Zhang; Nanzhe Zhong; Tianqi Fan; Xin Gao; Zhipeng Wu; Zhenxi Li; Tielong Liu; Jianru Xiao
Journal:  J Bone Oncol       Date:  2018-04-13       Impact factor: 4.072

7.  Kadsurenone is a useful and promising treatment strategy for breast cancer bone metastases by blocking the PAF/PTAFR signaling pathway.

Authors:  Tianhui Hou; Yan Lou; Shichang Li; Chenglong Zhao; Yingzheng Ji; Dongsheng Wang; Liang Tang; Ming Zhou; Wei Xu; Ming Qian; Zhipeng Wu; Jian Zhao; Haifeng Wei; Zhenxi Li; Jianru Xiao
Journal:  Oncol Lett       Date:  2018-06-08       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.